<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Lamivudine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00709</strong>&#160; (APRD00681)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (<span class="caps">HIV</span>-1) and hepatitis B (<span class="caps">HBV</span>).</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00709/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00709/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00709.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00709.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00709.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00709.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00709.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00709">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Lamivudin</td><td>German</td><td>INN</td></tr><tr><td>Lamivudina</td><td>Spanish</td><td>INN</td></tr><tr><td>Lamivudine</td><td>French</td><td>INN</td></tr><tr><td>Lamivudinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>3-TC</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000976/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000976/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000976">DBSALT000976</a></td>
      </tr>
      <tr>
        <td>
          <strong>GR 109714 X</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000977/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000977/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000977">DBSALT000977</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Amilitrap</td><td>Dosa</td></tr><tr><td>Antiheb</td><td>Mebiphar</td></tr><tr><td>Avilam</td><td>Beximco</td></tr><tr><td>Avolam</td><td>Ranbaxy Laboratories</td></tr><tr><td>Epivir</td><td>GlaxoSmithKline</td></tr><tr><td>Epivir-HBV</td><td>GlaxoSmithKline</td></tr><tr><td>Flamivud</td><td>Flamingo Pharmacueticals</td></tr><tr><td>Ganvirel</td><td>Ivax</td></tr><tr><td>Hepavir</td><td>Square</td></tr><tr><td>Hepitec</td><td>GlaxoSmithKline</td></tr><tr><td>Heptavir</td><td>Hetero</td></tr><tr><td>Heptodin</td><td>GlaxoSmithKline</td></tr><tr><td>Heptodine</td><td>GlaxoSmithKline</td></tr><tr><td>Heptovir</td><td>GlaxoSmithKline</td></tr><tr><td>Lamda</td><td>Cadila</td></tr><tr><td>Lamibergen</td><td>Paylos</td></tr><tr><td>Lamidac</td><td>Zydus</td></tr><tr><td>Lamitec</td><td>Zifam India</td></tr><tr><td>Lamivir</td><td>Incepta</td></tr><tr><td>Zeffix</td><td>GlaxoSmithKline</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Avocomb</td><td>Lamivudine and Zidovudine</td></tr><tr><td>Avudin</td><td>Lamivudine and Zidovudine</td></tr><tr><td>Biovir</td><td>Lamivudine and Zidovudine</td></tr><tr><td>Cipla-Duovir</td><td>Lamivudine and Zidovudine</td></tr><tr><td>Combid</td><td>Lamivudine + Zidovudine</td></tr><tr><td>Combivir</td><td>Lamivudine + Zidovudine</td></tr><tr><td>Coviro</td><td>Lamivudine and Stavudine</td></tr><tr><td>Cytocom</td><td>Lamivudine and Zidovudine</td></tr><tr><td>Cytocom-N</td><td>Lamivudine and Zidovudine, + Nevirapine</td></tr><tr><td>Epzicom</td><td>Abacavir Sulfate + Lamivudine</td></tr><tr><td>Ganvirel Duo</td><td>Lamivudine and Zidovudine</td></tr><tr><td>Kivexa</td><td>Abacavir Sulfate + Lamivudine</td></tr><tr><td>Lamda-Z</td><td>Lamivudine and Zidovudine</td></tr><tr><td>Lamitec-S</td><td>Lamivudine and Stavudine</td></tr><tr><td>Lamivir-S</td><td>Lamivudine and Stavudine</td></tr><tr><td>Trizivir</td><td>Abacavir Sulfate + Lamivudine + Zidovudine</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-hiv-agents">Anti-HIV Agents</a></li>
<li><a href="/mesh/reverse-transcriptase-inhibitors">Reverse Transcriptase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>134678-17-4</td></tr><tr><th>Weight</th><td>Average: 229.256<br>Monoisotopic: 229.052111923</td></tr><tr><th>Chemical Formula</th><td>C<sub>8</sub>H<sub>11</sub>N<sub>3</sub>O<sub>3</sub>S</td></tr><tr><th>InChI Key</th><td>JTEGQNOMFQHVDC-NKWVEPMBSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organooxygen Compounds</td></tr><tr><th>Class</th><td>Carbohydrates and Carbohydrate Conjugates</td></tr><tr><th>Subclass</th><td>Glycosyl Compounds</td></tr><tr><th>Direct parent</th><td>Pyrimidine Nucleosides and Analogues</td></tr><tr><th>Alternative parents</th><td>Aminopyrimidines and Derivatives; Pyrimidones; Primary Aromatic Amines; Hydropyrimidines; Dithioacetals; Oxathiolanes; Polyamines; Ethers; Primary Alcohols; Thioethers</td></tr><tr><th>Substituents</th><td>aminopyrimidine; pyrimidone; primary aromatic amine; pyrimidine; hydropyrimidine; thioacetal; oxathiolane; ether; thioether; polyamine; primary alcohol; alcohol; primary amine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the pyrimidine nucleosides and analogues. These are compounds comprising a pyrimidine base attached to a sugar.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of HIV infection and chronic hepatitis B (HBV).</td></tr><tr><th>Pharmacodynamics</th><td>Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV). Lamivudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.</td></tr><tr><th>Mechanism of action</th><td>Lamivudine is a synthetic nucleoside analogue and is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP). This nucleoside analogue is incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase, resulting in DNA chain termination.</td></tr><tr><th>Absorption</th><td>Lamivudine was rapidly absorbed after oral administration in HIV-infected patients. Absolute bioavailability in 12 adult patients was 86% &#177; 16% (mean &#177; SD) for the 150-mg tablet and 87% &#177; 13% for the oral solution. The peak serum lamivudine concentration (Cmax) was 1.5 &#177; 0.5 mcg/mL when an oral dose of 2 mg/kg twice a day was given to HIV-1 patients. When given with food, absorption is slower, compared to the fasted state. </td></tr><tr><th>Volume of distribution</th><td><p>Apparent volume of distribution, IV administration = 1.3 &#177; 0.4 L/kg. Volume of distribution was independent of dose and did not correlate with body weight.</p></td></tr><tr><th>Protein binding</th><td></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolism of lamivudine is a minor route of elimination. In man, the only known metabolite of lamivudine is the trans-sulfoxide metabolite. This biotransformation is catalyzed by sulfotransferases. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Lamivudine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000927" target="_blank">Sulfotransferase 1A1</a></li></ul></td><td><a href="/metabolites/DBMET00895">Lamivudine sulfoxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/916">Details</a></td></tr><tr><td>Lamivudine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000615" target="_blank">Choline-phosphate cytidylyltransferase A</a></li></ul></td><td><a href="/metabolites/DBMET00896">Lamivudine-diphosphate-choline</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/917">Details</a></td></tr><tr><td>Lamivudine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00897">Lamivudine-diphosphate-ethanolamine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/918">Details</a></td></tr><tr><td>Lamivudine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00898">Lamivudine-monophosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/919">Details</a></td></tr><tr><td>Lamivudine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00899">Lamivudine-triphosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/920">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>The majority of lamivudine is eliminated unchanged in urine by active organic cationic secretion. 5.2% &#177; 1.4% (mean &#177; SD) of the dose was excreted as the trans-sulfoxide metabolite in the urine. Lamivudine is excreted in human breast milk and into the milk of lactating rats.</td></tr><tr><th>Half life</th><td>5 to 7 hours (healthy or HBV-infected patients) </td></tr><tr><th>Clearance</th><td><ul>
	<li>Renal clearance = 199.7 &#177; 56.9 mL/min [300 mg oral dose, healthy subjects]</li>
	<li>Renal clearance = 280.4 &#177; 75.2 mL/min [single IV dose, <span class="caps">HIV</span>-1-infected patients]</li>
	<li>Total clearance = 398.5 &#177; 69.1 mL/min [<span class="caps">HIV</span>-1-infected patients]</li>
</ul></td></tr><tr><th>Toxicity</th><td>The most common reported adverse reactions (incidence &#8805;15%) in adults were headache, nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, and cough. </td></tr><tr><th>Affected organisms</th><td><ul><li>Human Immunodeficiency Virus</li>
<li>Hepatitis B virus</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Lamivudine Metabolism Pathway</td><td>Drug metabolism</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9932</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9792</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7147</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7523</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9561</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9803</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8646</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7476</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8393</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6393</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8687</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7933</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9206</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8282</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.831</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.887</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.6341
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.782
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9698
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1348 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9834
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8735
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Viiv healthcare co</li>
<li>Glaxosmithkline</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Dept Health Central Pharmacy</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.gsk.com">GlaxoSmithKline Inc.</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li>St Mary's Medical Park Pharmacy</li>
<li>Tya Pharmaceuticals</li>
<li>ViiV Healthcare ULC</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Oral</td><td>5 mg/mL, 10 mg/mL</td></tr><tr><td>Tablet</td><td>Oral</td><td>100 mg, 150 mg, 300 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01610">Valganciclovir</a></td><td>The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Lamivudine, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended.</td></tr><tr><td><a href="/drugs/DB00943">Zalcitabine</a></td><td>Lamivudine may reduce the efficacy of zalcitabine. Combination therapy is not recommended.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals. Food does not decrease the extent of absorption, but it decreases the Cmax by slowing the rate of absorption.</li></ul></td></tr></tbody></table>